Microfluidics‐Enabled Nanovesicle Delivers CD47/PD‐L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma
Advanced Science · 2023-07 · 10 (20)
DOI: 10.1002/advs.202206213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 03.05.2023. Verfasst von Zhenwei Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shenzhen Institute of Respiratory Diseases, Department of Clinical Medical Research Center, The…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Shenzhen Key Medical Discipline Construction Fund, Guangdong Provincial Key Laboratory of Advanced Biomaterials.
Abstract (Originalsprache)
The CD47/PD‐L1 antibodies combination exhibits durable antitumor immunity but also elicits excessive immune‐related adverse events (IRAEs) caused by the on‐target off‐tumor immunotoxicity, hindering their clinical benefits greatly. Here, a microfluidics‐enabled nanovesicle using ultra‐pH‐sensitive polymer mannose‐poly(carboxybetaine methacrylate)‐poly(hydroxyethyl piperidine methacrylate) (Man‐PCB‐PHEP) is developed to deliver CD47/PD‐L1 antibodies (NCPA) for tumor‐acidity‐activated immunotherapy. The NCPA can specifically release antibodies in acidic environment, thereby stimulating the phagocytosis of bone marrow‐derived macrophages. In mice bearing Lewis lung carcinoma, NCPA shows significantly improved intratumoral CD47/PD‐L1 antibodies accumulation, promoted tumor‐associated macrophages remodeling to antitumoral status, and increased infiltration of dendritic cells and cytotoxic T lymphocytes, resulting in more favorable treatment effect compared to those of free antibodies. Additionally, NCPA also shows less IRAEs, including anemia, pneumonia, hepatitis, and small intestinal inflammation in vivo. Altogether, a potent dual checkpoint blockade immunotherapy utilizing NCPA with enhanced antitumor immunity and reduced IRAEs is demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shenzhen Institute of Respiratory Diseases, Department of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, The First Affili…
- Guangdong Provincial Key Laboratory of Advanced Biomaterials, Shenzhen Key Laboratory of Smart Healthcare Engineering, Department of Biomedical Engineering, Southern University of Science and Technology, No. 1088 Xueyua…
- School of Medicine, Life and Health Sciences, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen, Guangdong, 518172, P. R. China.
- Department of Hematology and Oncology, Shenzhen Children's Hospital, 7019 Yitian Road, Shenzhen, Guangdong, 518038, P. R. China.
- Department of Pharmacology and International Cancer Center, Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China.
- Aier School of Ophthalmology, Central South University, Changsha, Hunan, 410083, P. R. China.
ORCID-Profile: Zhenwei Su, Xingyu Jiang, Chang Zou
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen Key Medical Discipline Construction Fund
- Guangdong Provincial Key Laboratory of Advanced Biomaterials
- Shenzhen Key Laboratory of Smart Healthcare Engineering
Zitieren
APA
Su, Z., Dong, S., Chen, Y., Huang, T., Qin, B., Yang, Q., Jiang, X., & Zou, C. (2023). Microfluidics‐Enabled Nanovesicle Delivers CD47/PD‐L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma. Advanced Science, 10(20). https://doi.org/10.1002/advs.202206213
Vancouver
Su Z, Dong S, Chen Y, Huang T, Qin B, Yang Q, et al. Microfluidics‐Enabled Nanovesicle Delivers CD47/PD‐L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma. Advanced Science. 2023;10(20). doi:10.1002/advs.202206213
BibTeX
@article{Su2023,
author = {Su, Zhenwei and Dong, Shaowei and Chen, Yao and Huang, Tuxiong and Qin, Bo and Yang, Qinhe and Jiang, Xingyu and Zou, Chang},
title = {Microfluidics‐Enabled Nanovesicle Delivers CD47/PD‐L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {20},
doi = {10.1002/advs.202206213}
}
EUVIMED